CL2021001725A1 - Compuestos para usarse como sustancias terapéuticamente activas en el tratamiento y/o prevención de enfermedades neurorretinianas. - Google Patents
Compuestos para usarse como sustancias terapéuticamente activas en el tratamiento y/o prevención de enfermedades neurorretinianas.Info
- Publication number
- CL2021001725A1 CL2021001725A1 CL2021001725A CL2021001725A CL2021001725A1 CL 2021001725 A1 CL2021001725 A1 CL 2021001725A1 CL 2021001725 A CL2021001725 A CL 2021001725A CL 2021001725 A CL2021001725 A CL 2021001725A CL 2021001725 A1 CL2021001725 A1 CL 2021001725A1
- Authority
- CL
- Chile
- Prior art keywords
- prevention
- treatment
- compounds
- active substances
- therapeutically active
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- -1 5-oxazolyl residue Chemical group 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 abstract 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 108091008695 photoreceptors Proteins 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/235,543 US10752593B2 (en) | 2018-12-28 | 2018-12-28 | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001725A1 true CL2021001725A1 (es) | 2021-12-17 |
Family
ID=69188012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001725A CL2021001725A1 (es) | 2018-12-28 | 2021-06-25 | Compuestos para usarse como sustancias terapéuticamente activas en el tratamiento y/o prevención de enfermedades neurorretinianas. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10752593B2 (enExample) |
| EP (1) | EP3902606A1 (enExample) |
| JP (1) | JP2022516086A (enExample) |
| KR (1) | KR20210110849A (enExample) |
| CN (1) | CN113301958A (enExample) |
| AU (1) | AU2019414950A1 (enExample) |
| BR (1) | BR112021011599A2 (enExample) |
| CA (1) | CA3125278A1 (enExample) |
| CL (1) | CL2021001725A1 (enExample) |
| EA (1) | EA202191057A1 (enExample) |
| IL (1) | IL284298A (enExample) |
| MX (1) | MX2021007813A (enExample) |
| PH (1) | PH12021551092A1 (enExample) |
| SG (1) | SG11202104958UA (enExample) |
| WO (1) | WO2020140043A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| AU2020454040B2 (en) | 2020-06-19 | 2025-03-06 | Endogena Therapeutics, Inc. | New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066675A (en) | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| CA2216439A1 (en) | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
| AU1920501A (en) | 1999-12-03 | 2001-06-12 | Alcon Universal Limited | The use of caspase 9 inhibitors to treat ocular neural pathology |
| JP2011506445A (ja) | 2007-12-13 | 2011-03-03 | アムジエン・インコーポレーテツド | γ−セクレターゼ調節剤 |
| US9018202B2 (en) | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| US20130046003A1 (en) | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| WO2014079850A1 (en) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted heterocyclic derivatives |
| DE102013110714A1 (de) | 2013-09-27 | 2015-04-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung |
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
-
2018
- 2018-12-28 US US16/235,543 patent/US10752593B2/en not_active Expired - Fee Related
-
2019
- 2019-12-27 MX MX2021007813A patent/MX2021007813A/es unknown
- 2019-12-27 AU AU2019414950A patent/AU2019414950A1/en not_active Abandoned
- 2019-12-27 SG SG11202104958UA patent/SG11202104958UA/en unknown
- 2019-12-27 CA CA3125278A patent/CA3125278A1/en active Pending
- 2019-12-27 WO PCT/US2019/068759 patent/WO2020140043A1/en not_active Ceased
- 2019-12-27 CN CN201980085675.1A patent/CN113301958A/zh active Pending
- 2019-12-27 BR BR112021011599-4A patent/BR112021011599A2/pt not_active Application Discontinuation
- 2019-12-27 EP EP19842557.1A patent/EP3902606A1/en not_active Withdrawn
- 2019-12-27 JP JP2021537220A patent/JP2022516086A/ja not_active Withdrawn
- 2019-12-27 EA EA202191057A patent/EA202191057A1/ru unknown
- 2019-12-27 KR KR1020217023914A patent/KR20210110849A/ko not_active Ceased
-
2021
- 2021-05-11 PH PH12021551092A patent/PH12021551092A1/en unknown
- 2021-06-22 IL IL284298A patent/IL284298A/en unknown
- 2021-06-25 CL CL2021001725A patent/CL2021001725A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113301958A (zh) | 2021-08-24 |
| EP3902606A1 (en) | 2021-11-03 |
| JP2022516086A (ja) | 2022-02-24 |
| EA202191057A1 (ru) | 2021-10-07 |
| IL284298A (en) | 2021-08-31 |
| KR20210110849A (ko) | 2021-09-09 |
| CA3125278A1 (en) | 2020-07-02 |
| US20200207719A1 (en) | 2020-07-02 |
| US10752593B2 (en) | 2020-08-25 |
| BR112021011599A2 (pt) | 2021-08-31 |
| PH12021551092A1 (en) | 2021-12-06 |
| AU2019414950A1 (en) | 2021-06-03 |
| SG11202104958UA (en) | 2021-07-29 |
| WO2020140043A1 (en) | 2020-07-02 |
| MX2021007813A (es) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| PY2240956A (es) | Nuevos Compuestos bicíclicos y sus usos | |
| PY2146661A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| PE20190705A1 (es) | COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING | |
| PE20212077A1 (es) | Nuevos compuestos sulfonamida de carboxamida | |
| PE20221341A1 (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| AR119126A1 (es) | Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vih | |
| UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
| AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
| CL2020000860A1 (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. | |
| AR088668A1 (es) | Moleculas pequeñas que contienen boro | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR061955A1 (es) | Compuestos quimicos | |
| PE20212070A1 (es) | Moduladores de trex1 | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
| AR081893A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina | |
| CO2018010787A2 (es) | Compuesto de griseofulvina | |
| AR120865A1 (es) | Tieniloxazolonas y análogos utilizados en el control de enfermedades de plantas | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| ECSP088172A (es) | Metodos para tratar la epileptogenesis | |
| CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
| AR132992A1 (es) | Agonistas de trem2 |